Form D · Biotechnology

IMMUNIC, INC.

New York, X1 · CIK 0001280776

Offering snapshot reported Mar 4, 2026 · SEC filing

Reported sold
$200M
Offering amount: $200M
Investors reported
43
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Feb 17, 2026
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Mar 4, 2026Initial$200,000,000No comparison43SEC filing
Jan 19, 2024Initial$80,000,016No comparison19SEC filing
Oct 18, 2022Initial$60,000,002No comparison14SEC filing
Mar 7, 2014Amendment$13,928,129$1,928,129vs Feb 4, 201437SEC filing
Feb 4, 2014Initial$12,000,000No comparison20SEC filing
Jan 31, 2014Amendment$31,979,470$9,439,131vs Jun 24, 201362SEC filing
Jun 24, 2013Amendment$22,540,339$8,280,339vs Mar 14, 201315SEC filing
Mar 14, 2013Initial$14,260,000No comparison12SEC filing
Nov 7, 2012Amendment$86,145,589$10,000,000vs Oct 9, 201240SEC filing
Oct 9, 2012Initial$76,145,589No comparison11SEC filing
Jun 22, 2012Initial$2,500,000No comparison1SEC filing
Feb 17, 2012Initial$929,831No comparison7SEC filing
Jun 23, 2011Initial$22,617,179No comparison51SEC filing
Jun 22, 2011Amendment$16,251,091$2,209,999vs Feb 7, 201142SEC filing
Feb 7, 2011Amendment$14,041,092$650,000vs Jan 4, 201142SEC filing
Jan 4, 2011Amendment$13,391,092$902,759vs Oct 15, 201042SEC filing
Oct 15, 2010Amendment$12,488,333$3,000,000vs Jul 1, 201042SEC filing
Jul 1, 2010Amendment$9,488,333$329,386vs Jun 23, 201041SEC filing
Jun 23, 2010Amendment$9,158,947$1,913,878vs May 14, 201041SEC filing
May 14, 2010Amendment$7,245,069$1,337,621vs Mar 18, 201041SEC filing
Mar 18, 2010Amendment$5,907,448$1,942,013vs Dec 10, 200941SEC filing
Dec 10, 2009Amendment$3,965,435$229,026vs Oct 28, 200941SEC filing
Oct 28, 2009Amendment$3,736,409$2,578,154vs Oct 7, 200934SEC filing
Oct 7, 2009Initial$1,158,255No comparison32SEC filing
Sep 14, 2007PaperNot reportedNo comparisonNot reportedSEC filing
Oct 28, 2005PaperNot reportedNo comparisonNot reportedSEC filing
Feb 10, 2005PaperNot reportedNo comparisonNot reportedSEC filing

Offering details

Securities
Equity, Option to acquire, Security to be acquired
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$12M
Finders' fees
$0
Form D file number
021-575474
6% of the aggregate gross proceeds received by the Company (i) upon the issuance of the Warrants at closing and (ii) upon the cash exercise of the Common Warrants.

Sales compensation recipients

Scroll to see all columns →

RecipientCRDAssociated broker-dealer
Leerink Partners LLC000039011
STIFEL, NICOLAUS & COMPANY, INCORPORATED000000793
GUGGENHEIM SECURITIES, LLC000040638
WILLIAM BLAIR & COMPANY, LLC000001252
LIFESCI CAPITAL LLC000168404
B. RILEY SECURITIES, INC.000025027
BROOKLINE CAPITAL MARKETS, A DIVISION OF ARCADIA SECURITIES, LLC000044656

Source: Form D, filed Mar 4, 2026. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Robert A. Ashley Executive
Jean Jacques Bienaime Director
Phillip M. Croxford Director
Douglas E. Godshall Director
Errol R. Halperin Director
Andrew Henry Executive
Tamar Howson Director
Ross A. Jaffe Director
Hella Kohlhof Executive
Charles Liamos Director
Andrea Loewen Executive
Kameron Maxwell Executive
Kemeron Maxwell Executive
J. Michael Millis Director
Andreas Muehler Executive
Richard Murawski Executive
Thorvald Nagel Director
Duane Nash Director
Jorg Neerman Director
Joerg Neerman Director
Jorg Neermann Director
Vincent Ossipow Director
Barclay Phillips Director
Richard Rudick Director
Muneer A, Satter Director
Lowell E. Sears Director
Inderpal Singh Executive
Simona Skerjanec Director
Jan Stange Executive
Randolph C. Steer Director
Aron P. Stern Executive
Michael V. Swanson Executive
Jason Tardio Executive
Maria Tornsen Director
Monika Maria Tornsen Director
Daniel Vitt Director, Executive
Patrick Walsh Executive
Glenn Whaley Executive
Terence E. Winters Director, Executive
Terry Winters Director, Executive

Issuer details

Industry: Biotechnology (See others in industry)

Address:
1200 Avenue Of The Americas Suite 200
New York, X1, 10036